Federal Express Corporation (FedEx), one of the world's largest express transportation companies, announced that its hubs at Guangzhou Baiyun International Airport, China (CAN) and Kansai International Airport, Japan (KIX) have been awarded the CEIV Pharma Corporate Certification — a nod to the company's ongoing commitment to quality and complianc in pharmaceutical logistics.

The Centre of Excellence for Independent Validators (CEIV) Pharma Certification, from the International Air Transport Association (IATA), ensures the highest standards in the handling and transportation of time and temperature-sensitive healthcare products such as pharmaceuticals and vaccines across air networks.

FedEx noted that the corporate-level certification is a testament to the strength of FedEx's quality management system and its expertise in delivering fully compliant, end-to-end logistic services that meet the rigorous demands of the increasingly complex and highly regulated pharmaceutical industry.

"Healthcare innovation demands smarter, faster, and more resilient supply chains," said Kawal Preet, president, Asia Pacific, FedEx.

"As Asia Pacific rapidly emerges as a global hub for clinical trials and biopharma manufacturing, the need for secure, compliant, and technology-enabled logistics is more important than ever. Our proven expertise in building intelligent cold chain solutions is designed to protect product integrity, ensure regulatory compliance, and deliver peace of mind to our customers."

"By combining our global network with AI-driven logistics and real-time monitoring, FedEx is helping healthcare and life sciences companies unlock speed, scale, and reliability, supporting the next wave of healthcare innovation across the region," Preet added.

FedEx noted that the Asia Pacific Pharmaceutical Logistics market is projected to grow from US$163 billion in 2025 to US$225 billion by 2030, reflecting a CAGR of 6.68%.

Additionally, the region accounts for approximately 50% of global clinical trials, highlighting its vital role in global pharmaceutical research and development.

FedEx noted that its customers in the healthcare and pharmaceutical sector need closed-loop temperature-controlled services to preserve temperature integrity to ensure product efficacy.

FedEx noted that it supports clinical trials, biologics, and vaccine shipments through its International Express network, Time Critical Special Services (SpS), and Life Science Centres in key global locations, including Incheon, Singapore, Tokyo, Mumbai, Memphis, and Veldhoven. Its healthcare infrastructure includes more than 130 cold-chain facilities worldwide, ensuring temperature-controlled transport.

"The certifications at Guangzhou Baiyun International Airport, China (CAN) and Kansai International Airport, Japan (KIX) are part of a broader FedEx initiative to expand CEIV-compliant infrastructure globally," FedEx said.

As of May 2025, a total of 19 FedEx facilities worldwide, including key locations in Europe and the Americas, will operate under the CEIV Pharma quality framework, further strengthening the company's position as a trusted logistics partner for the global healthcare industry.